Lexicon Pharmaceuticals, Inc
Lexicon Pharmaceuticals is a biopharmaceutical company dedicated to pioneering medicines that transform patients' lives through innovative science, including a unique application of gene science. They focus on developing therapies for various conditions, including neuropathic pain and cardiometabolic diseases, with a mission driven by patient needs and cutting-edge research.
Industries
Nr. of Employees
medium (51-250)
Lexicon Pharmaceuticals, Inc
The Woodlands, Texas, United States, North America
Products
Sotagliflozin (SGLT1/2 inhibitor)
Clinical development program for an SGLT1/2 inhibitor with indications including heart failure; development stages listed from preclinical through approved in the public pipeline table.
Pilavapadin (AAK1 inhibitor)
Clinical development program for an AAK1 inhibitor being developed for diabetic peripheral neuropathic pain and postherpetic neuralgia as listed in the public pipeline.
LX9851
Clinical development program listed for obesity/weight management in the public pipeline.
INPEFA (marketed product reference)
Listed product in site navigation indicating marketed product availability (product details accessible via product page).
Sotagliflozin (SGLT1/2 inhibitor)
Clinical development program for an SGLT1/2 inhibitor with indications including heart failure; development stages listed from preclinical through approved in the public pipeline table.
Pilavapadin (AAK1 inhibitor)
Clinical development program for an AAK1 inhibitor being developed for diabetic peripheral neuropathic pain and postherpetic neuralgia as listed in the public pipeline.
LX9851
Clinical development program listed for obesity/weight management in the public pipeline.
INPEFA (marketed product reference)
Listed product in site navigation indicating marketed product availability (product details accessible via product page).
Services
Expanded access request review and handling
Evaluate and respond to physician-submitted expanded access requests for investigational medicines, including clinical evaluation, supply assessment, and timelines for acknowledgement.
Collaboration and licensing partnerships
Negotiation and execution of collaborations, strategic alliances, and royalty/milestone arrangements for discovery, development, and commercialization.
Investigator-initiated study and grant support
Support and formal request processes for investigator-initiated studies, sponsorships, educational grants and charitable donations.
Adverse event intake and reporting
Point of contact and processes for receiving adverse event or product quality complaints and directing reports to regulatory authorities as appropriate.
Expanded access request review and handling
Evaluate and respond to physician-submitted expanded access requests for investigational medicines, including clinical evaluation, supply assessment, and timelines for acknowledgement.
Collaboration and licensing partnerships
Negotiation and execution of collaborations, strategic alliances, and royalty/milestone arrangements for discovery, development, and commercialization.
Investigator-initiated study and grant support
Support and formal request processes for investigator-initiated studies, sponsorships, educational grants and charitable donations.
Adverse event intake and reporting
Point of contact and processes for receiving adverse event or product quality complaints and directing reports to regulatory authorities as appropriate.
Expertise Areas
- Clinical trial management
- Drug discovery and target identification
- Precision / gene-science approaches
- Cardiometabolic therapeutics
Key Technologies
- Gene-science–based discovery platform
- Target identification and validation
- Small-molecule inhibitor development
- Clinical development platforms (Phase I–III)